Daily Ards Research Analysis
Therapeutic, physiologic, and imaging advances in ARDS emerged across three studies. An airway-delivered encapsulated cell platform achieved localized, durable cytokine delivery with efficacy in rodent ARDS and safety in a large-animal model; longitudinal mechanical power trajectories predicted mortality; and a CT radiomics–clinical nomogram improved 28-day mortality prediction in older patients with sepsis-induced ARDS.
Summary
Therapeutic, physiologic, and imaging advances in ARDS emerged across three studies. An airway-delivered encapsulated cell platform achieved localized, durable cytokine delivery with efficacy in rodent ARDS and safety in a large-animal model; longitudinal mechanical power trajectories predicted mortality; and a CT radiomics–clinical nomogram improved 28-day mortality prediction in older patients with sepsis-induced ARDS.
Research Themes
- Localized airway immunomodulation using encapsulated cytokine-secreting cells
- Longitudinal ventilator mechanical power trajectories and mortality risk
- CT radiomics–clinical fusion models for mortality prediction in sepsis-induced ARDS
Selected Articles
1. Airway Delivery of Encapsulated Cytokine-Secreting Cells for Local Immunomodulation in Inflammatory Lung Diseases.
A modular, airway-deliverable microcapsule platform enables localized, durable release of IL-10 or IL-1Ra, attenuating inflammation in a rodent ARDS model and improving hypoxemia and structure in pulmonary fibrosis. Single-cell RNA-seq shows myeloid reprogramming, and large-animal testing supports safety, highlighting translational potential for ARDS and other inflammatory lung diseases.
Impact: Introduces a first-in-class airway cell-encapsulation platform achieving localized immunomodulation with multi-model efficacy and large-animal safety—addressing systemic toxicity barriers that have limited ARDS immunotherapies.
Clinical Implications: Not yet practice-changing, but supports a therapeutic avenue for localized anti-inflammatory treatment in ARDS to avoid systemic adverse events; informs design of first-in-human trials (dose, durability, airway delivery).
Key Findings
- Airway-delivered microcapsules enabled localized, durable delivery of IL-10 and IL-1Ra in the lung.
- In a rodent ARDS model, localized IL-10 or IL-1Ra reduced inflammatory signaling and injury.
- Single-cell RNA sequencing showed IL-10 capsules reprogrammed myeloid composition and suppressed pro-inflammatory genes.
- In a bleomycin model, sustained IL-10 delivery improved hypoxemia and rescued lung architecture.
- Large-animal studies supported safety and biocompatibility of the airway-delivered capsules.
Methodological Strengths
- Multiple in vivo models (rodent ARDS and pulmonary fibrosis) plus large-animal safety assessment
- Single-cell RNA sequencing to mechanistically map immune reprogramming
Limitations
- Preclinical study; no human efficacy data yet and not peer-reviewed (preprint)
- Long-term safety, dosing, and retention kinetics in diseased human lungs remain undefined
Future Directions: Proceed to GLP toxicology, device–procedure optimization for bronchoscopic delivery, and phase 1 trials focusing on safety, pharmacodynamics, and biomarker-guided dose in ARDS.
Dysregulated lung immunity drives excessive inflammation, leading to diseases like acute respiratory distress syndrome (ARDS) and pulmonary fibrosis that have high morbidity and mortality. Immunomodulation can attenuate inflammation and improve outcomes, however off-target effects from systemic delivery lead to adverse events that limit clinical translation. Herein, we develop a modular cell-based microcapsule platform that can be administered via the airway for localized, durable, and tunable delivery of various immunomodulatory proteins to the lungs. With this system, we demonstrate therapeutic efficacy of localized delivery of two proteins, interleukin-10 (IL-10) and interleukin-1 receptor antagonist (IL-1Ra), in a lipopolysaccharide-induced rodent model of ARDS. Single-cell RNA sequencing revealed that IL-10-secreting capsules reprogram the lung immune landscape in ARDS by altering myeloid cell composition, suppressing pro-inflammatory gene expression, and promoting the resolution of inflammation. In a bleomycin pulmonary fibrosis model, the platform enables durable and sustained delivery of IL-10 to alleviate hypoxemia and rescue lung architecture. Safety and biocompatibility were further confirmed in a large animal model, highlighting the clinical potential of the platform for the treatment of inflammatory lung diseases.
2. Trajectory patterns of mechanical power and prognosis in ARDS: a longitudinal analysis using group-based trajectory modeling.
Using MIMIC-IV longitudinal data and group-based trajectory modeling, three mechanical power trajectories (low, medium, high) were identified in ARDS. High mechanical power trajectory independently associated with higher 28-day mortality (adjusted OR 1.33), offering a dynamic risk metric beyond single timepoints.
Impact: Links time-evolving ventilator energy load to mortality, supporting trajectory-based targets for ventilator management and potential interventional strategies.
Clinical Implications: Monitoring and minimizing mechanical power over time, not just at single snapshots, may reduce mortality risk; trajectory classification could inform alerts and ventilator titration.
Key Findings
- Identified three distinct mechanical power trajectories (low, medium, high) in 1,439 ARDS patients.
- High mechanical power trajectory was associated with increased 28-day mortality (adjusted OR 1.33; 95% CI 1.05–1.68; P=0.017).
- Higher mechanical power correlated with increased PaO2, PaCO2, ventilation parameters (VE, VT, Pplat, PEEP, FiO2, peak pressure) and labs (WBC, creatinine, BUN).
Methodological Strengths
- Large, well-curated ICU database with longitudinal ventilator data
- Use of group-based trajectory modeling and multivariable adjustment
Limitations
- Retrospective single-database analysis with potential residual confounding
- Effect size is modest and physiologic drivers (e.g., effort, esophageal pressure) were not directly measured
Future Directions: Prospective trials testing ventilator strategies to lower mechanical power trajectories; integration into real-time decision support to maintain patients on low-power paths.
OBJECTIVE: Mechanical power has been identified as a predictor of prognosis in ARDS; however, previous studies based on cross-sectional data may fail to capture the dynamic pathophysiological changes and progression of pulmonary conditions. This study aimed to investigate the association between mechanical power trajectories and 28-day mortality using longitudinal data. METHODS: Data were extracted from the Medical Information Mart for Intensive Care IV (MIMIC-IV, version 2.2) database. Mechanical power was divided into quartiles to compare distribution characteristics and temporal trends across groups. Group-based trajectory modeling (GBTM) identified distinct mechanical power trajectories. Multivariate logistic regression analyzed the association between trajectory groups and 28-day mortality. RESULTS: A total of 1,439 eligible patients were included. Stratification by mechanical power quartiles showed that higher mechanical power was associated with increases in arterial oxygen partial pressure, carbon dioxide, serum creatinine, blood urea nitrogen, potassium, hemoglobin, white blood cell count, respiratory rate, minute ventilation, tidal volume, plateau pressure, positive end-expiratory pressure, FiO₂, and peak airway pressure (all P for trend < 0.001). GBTM identified three trajectories classified as low, medium, and high mechanical power groups. Multivariate logistic regression revealed that compared to the low-power group, the high-power group had a significantly higher risk of 28-day mortality after full adjustment (P = 0.017; OR 1.33; 95% CI 1.05-1.68). CONCLUSION: Distinct mechanical power trajectories in ARDS patients were identified and shown to be associated with 28-day mortality, providing practical insights for ventilator management optimization.
3. Prognostic assessment of sepsis-induced acute respiratory distress syndrome in older patients using clinical and CT-based radiomic features.
In 302 older SI-ARDS patients, a CT radiomics–clinical fusion model achieved superior 28-day mortality prediction (C-index 0.850 training; 0.839 validation) with good calibration and net benefit, outperforming SOFA and single-domain models. A nomogram enabled risk stratification into distinct survival groups.
Impact: Demonstrates clinically actionable, imaging-augmented risk prediction tailored to older SI-ARDS, a high-risk subgroup often underrepresented in models.
Clinical Implications: Supports early risk stratification at admission to guide monitoring intensity, resource allocation, and trial enrollment for older SI-ARDS patients.
Key Findings
- A fusion radiomics–clinical model yielded C-index 0.850 (training) and 0.839 (validation) for 28-day mortality.
- Outperformed SOFA and single-domain (radiomics-only or clinical-only) models with better calibration and decision-curve net benefit.
- Nomogram-based risk stratification separated patients into distinct survival groups (log-rank p<0.001).
Methodological Strengths
- Rigorous feature selection (MRMR and LASSO) with separate training/validation cohorts
- Comprehensive evaluation including calibration and decision curve analysis
Limitations
- Single-center retrospective study with a relatively small validation cohort (n=60)
- CT acquisition/segmentation variability and lack of external multicenter validation
Future Directions: External, multicenter validation and prospective impact studies; harmonization of CT protocols and automated segmentation to facilitate clinical deployment.
BACKGROUND: Sepsis-induced acute respiratory distress syndrome (SI-ARDS) is associated with high mortality rates, necessitating early risk stratification. This study aimed to develop and validate a radiomics-based nomogram integrating computed tomography (CT) features and clinical parameters to predict 28-day mortality in older patients with SI-ARDS. METHODS: In this retrospective cohort study, 302 older patients (≥60 years) diagnosed with SI-ARDS between January 2019 and December 2023 were enrolled. Radiomic features were extracted from admission chest CT images. Patients were randomly allocated to training (n = 242) and validation (n = 60) cohorts. Three predictive models-radiomic, clinical, and combined-were constructed using Maximum Relevance Minimum Redundancy (MRMR) algorithm and Least Absolute Shrinkage and Selection Operator (LASSO) regression. Model performance was assessed using the concordance index (C-index), calibration curves, and decision curve analysis. A nomogram was developed based on the optimal model for clinical application. RESULTS: The fusion model achieved superior discrimination compared with the radiomic model, clinical model, and Sequential Organ Failure Assessment score in both cohorts (C-index: training, 0.850 vs. 0.798, 0.781, and 0.654; validation, 0.839 vs. 0.768, 0.779, and 0.696; all p < 0.001). The model demonstrated excellent calibration and provided greater net clinical benefit across threshold probabilities of 10 %-90 %. Risk stratification using the nomogram identified distinct prognostic groups with significantly different 28-day survival (log-rank p < 0.001). CONCLUSION: The nomogram developed from the fusion model demonstrated superior predictive performance for 28-day mortality in older patients with SI-ARDS compared to conventional scoring systems, though multicenter validation is required to confirm clinical utility.